Bluejay Diagnostics, Inc.

What they do

Bluejay is developing the Symphony platform, an analyzer plus single-use protein detection cartridges designed to produce laboratory-quality results in approximately 20 minutes in ICUs and emergency rooms. The lead product candidate is the Symphony IL-6 test, an immunoassay measuring interleukin-6 for monitoring disease progression in critical care, which the company is pursuing in the context of sepsis. The company does not yet have FDA clearance and must obtain regulatory authorization before Symphony can be marketed in the United States.

Revenue drivers

• Symphony IL-6 test (lead product candidate) — Intended to be the first commercial product, generating revenue from cartridge and analyzer sales in critical care settings if it receives FDA clearance; the company currently has no product revenue and sells nothing today.
• Symphony platform expansion tests — Future potential tests for cardiac biomarkers hsTNT and NT pro-BNP for myocardial infarction and congestive heart failure, described only as future hopes with no revenue today.
• Investment income on cash balances — The company's only reported income is interest income, such as $43,688 for the six months ended June 30, 2026 and $97,559 for the year ended December 31, 2025; there is no product revenue.

Recent performance

For the six months ended June 30, 2026, Bluejay reported a net loss of approximately $4.2 million, compared with approximately $3.8 million for the same period in 2025. Research and development expense rose to $2,249,643 from $1,674,696, while general and administrative expense fell to $2,038,312 from $2,199,582. Operating cash flow was negative $3.1 million for the first half of 2026, versus negative $3.2 million a year earlier. As of June 30, 2026, cash and cash equivalents were approximately $9.6 million, total liabilities were $2.1 million and shareholders' equity was $9.4 million. Accumulated deficit reached approximately $45.8 million as of June 30, 2026.

Strategy

Bluejay's stated priorities are completing the SYMON-II pivotal clinical trial, qualifying Symphony cartridges with contract manufacturer Sanyoseiko, and preparing a 510(k) submission to the FDA in 2027. During 2026, the company transferred cartridge production from Toray Industries to an FDA-certified Sanyoseiko facility and worked to resolve technical manufacturing issues. The current plan is to complete analytical and clinical testing of SYMON-II samples by the end of 2026. In the 10-Q, management said it expects to need to raise between $10.0 million and $14 million between the filing date and the end of fiscal 2027, in various tranches; the 10-K framed the need as at least $20 million. Sales and marketing spending was eliminated in 2025 as the company focused on development.

Risks

• No product revenue or FDA clearance — Bluejay has never generated product revenue and cannot market Symphony in the United States unless the FDA clears it; the company states it may never achieve or maintain profitability.
• Going concern and financing need — Management disclosed that it will need to raise a material amount of additional capital to continue as a going concern, and that absent near-term financing or strategic alternatives it could pursue liquidation under U.S. bankruptcy laws.
• Manufacturing and cartridge readiness risk — Cartridges manufactured by Sanyoseiko are still being produced and verified to meet FDA submission and commercial production requirements, and SYMON-II sample testing depends on these cartridges being ready.
• Clinical and regulatory timing risk — SYMON-II has enrolled approximately 680 patients toward a target of 750 as of May 5, 2026; patient testing has not yet begun, and the company's 510(k) timeline depends on subsequent analytical and clinical validation.

Outlook

Management says it expects to complete SYMON-II patient enrollment in the summer of 2026 and to analyze blood samples with the Symphony IL-6 test in the third quarter of 2026, with a goal of being positioned to submit a 510(k) application in 2027 and an objective of FDA clearance thereafter. The 10-Q plan is to complete analytical and clinical testing of SYMON-II samples by the end of 2026. Funding that plan requires new capital in tranches, and management has stated that if financing is not obtained in the near term it could undertake a liquidation process.